Transthyretin as a potential serological marker for the diagnosis of patients with early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 394-399

  Ni, M ^a   Wei, W ^a   Feng, Q ^b   Sun, X G ^a   Wang, Y C ^a   Gu, Y J ^a   Zheng, F ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Central Hospital of Gynecology Obstetrics   (China)

Author keywords

MALDI TOF MS; Osteoarthritis; Rheumatoid arthritis; Transthyretin

Indexed keywords

PREALBUMIN;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN MODIFICATION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PREALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84878354984     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. SHERRER YS, BLOCH DA, MITCHELL DM, YOUNG DY, FRIES JF: The development of disability in rheumatoid arthritis. Arthritis Rheum 1986; 29: 494-500.
2. SCOTT DL, SYMMONS DP, COULTON BL, POPERT AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1: 1108-11.
3. FELDMANN M, BRENNAN FM, MAINI RN: Rheumatoid arthritis. Cell 1996; 85: 307-10.
4. ALLAART CF, BREEDVELD FC, DIJKMANS BA: Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 2007; 80: 25-33.
5. SCHOELS M, KNEVEL R, ALETAHA D et al.: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-43.
6. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. VISSER H, LE CESSIE S, VOS K, BREEDVELD FC, HAZES JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
8. ALETAHA D, NEOGI T, SILMAN AJ et al.: Rheumatoid Arthritis Classification Criteria. Arthritis Rheum 2010; 62: 2569-81.
9. LALVANI A, MERONI PL, MILLINGTON KA et al.: Recent advances in diagnostic technology: applications in autoimmune and infectious diseases. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S62-6.
10. ZHANG H, FAN LY, ZONG M, SUN LS, LU L: Proteins related to the functions of fibroblastlike synoviocytes identified by proteomic analysis. Clin Exp Rheumatol 2012; 30: 213-21.
11. GIUSTI L, BALDINI C, CIREGIA F et al.: Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis? Proteomics Clin Appl 2010; 4: 315-24.
12. DE SENY D, FILLET M, MEUWIS MA et al.: Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 2005; 52: 3801-12.
13. NAISHIRO Y, SUZUKI C, KIMURA M et al.: Plasma analysis of rheumatoid arthritis by SELDI. Nihon Rinsho Meneki Gakkai Kaishi 2007; 30: 145-50.
14. AN Y, PU H, HE SZ, LI ZG: Identification of biomarkers in serum of early rheumatoid arthritis by proteomic methods. Zhonghua Yi Xue Za Zhi 2005; 85: 1261-5.
15. LIM A, SENGUPTA S, MCCOMB ME et al.: In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 2003; 278: 49707-13.
16. ROSTOM AA, SUNDE M, RICHARDSON SJ et al.: Dissection of multi-protein complexes using mass spectrometry: subunit interactions in transthyretin and retinol-binding protein complexes. Proteins 1998; (Suppl. 2): 3-11.
17. CONNORS LH, LIM A, PROKAEVA T, ROSKENS VA, COSTELLO CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10: 160-84.
18. HOU X, AGUILAR MI, SMALL DH: Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007; 274: 1637-50.
19. KOZAK KR, SU F, WHITELEGGE JP et al.: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589-96.
20. LIU L, LIU J, DAI S et al.: Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007; 98: 1617-24.
21. LIM A, PROKAEVA T, MCCOMB ME et al.: Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal Chem 2002; 74: 741-51.
22. SHIMIZU A, NAKANISHI T, MIYAZAKI A: Detection and characterization of variant and modified structures of proteins in blood and tissues by mass spectrometry. Mass Spectrom Rev 2006; 25: 686-712.
23. TACHIBANA N, TOKUDA T, YOSHIDA K et al.: Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 1999; 6: 282-8.
24. HEINOLD A, KUEHL B, BRENNER-WEISS G, OPELZ G, TRAN TH: Sequential analysis by immunoprecipitation-MALDI-TOF: a novel method for detection and identification of alloantibody specificities. Hum Immunol 2010; 71: 462-7.
25. GRUS FH, JOACHIM SC, SANDMANN S et al.: Transthyretin and complex protein pattern in aqueous humor of patients with primary openangle glaucoma. Mol Vis 2008; 14: 1437-45.
26. DUGGAN A, HUFFMAN FG: Validation of serum transthyretin (prealbumin) as a nutritional parameter in hemodialysis patients. J Ren Nutr 1998; 8: 142-9.
27. TAKEUCHI T, NAKANISHI T, TABUSHI Y et al.: Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab). J Chromatogr B Analyt Technol Biomed Life Sci 2007; 855: 66-70.
28. LIM A, PROKAEVA T, MCCOMB ME, CONNORS LH, SKINNER M, COSTELLO CE: Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci 2003; 12: 1775-85.
29. BULAWA CE, CONNELLY S, DEVIT M et al.: Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci 2012; 109: 9629-34.
30. KINGSBURY JS, LAUE TM, KLIMTCHUK ES, THEBERGE R, COSTELLO CE, CONNORS LH: The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. J Biol Chem 2008; 283: 11887-96.
31. BIROCCIO A, DEL BOCCIO P, PANELLA M et al.: Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006; 6: 2305-13.
32. UEDA M, MISUMI Y, MIZUGUCHI M et al.: SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 2009; 55: 1223-7.
33. ZHAO H, LIU JP, ZHENG F et al.: Chemical modification of transthyretin in familial amyloidotic polyneuropathy. J Fourth Mil Med Univ 2008; 29: 883-85.